Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel Versus Oral Administration of Levodopa-Carbidopa Tablets in Japanese Subjects with Advanced Parkinson's Disease: Pharmacokinetics and Pilot Efficacy and Safety

被引:18
作者
Othman, Ahmed A. [1 ,2 ]
Chatamra, Krai [3 ]
Mohamed, Mohamed-Eslam F. [1 ]
Dutta, Sandeep [1 ]
Benesh, Janet [3 ]
Yanagawa, Masayoshi [4 ]
Nagai, Masahiro [5 ]
机构
[1] AbbVie, Clin Pharmacol & Pharmacometr, N Chicago, IL 60064 USA
[2] Cairo Univ, Fac Pharm, Dept Pharmaceut, Cairo, Egypt
[3] AbbVie, Dept Neurosci, N Chicago, IL 60064 USA
[4] AbbVie GK, Tokyo, Japan
[5] Ehime Univ Hosp, Clin Therapeut Trial Ctr, Toon, Ehime, Japan
关键词
MOTOR FLUCTUATIONS; DOUBLE-BLIND; ABSORPTION;
D O I
10.1007/s40262-015-0265-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson's disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa-carbidopa intestinal gel (LCIG) provides individualized continuous levodopa-carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD. Methods Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed. Results Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased "Off" time (2.68 h, P = 0.002) and increased "On" time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary((c)). With the small sample size, no statistically significant changes were seen on other efficacy endpoints. Conclusions In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations.
引用
收藏
页码:975 / 984
页数:10
相关论文
共 23 条
[1]  
Abbott Japan Co. Ltd, NCT01479127 US NIH C
[2]  
AbbVie, NCT01960842 US NIH C
[3]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[4]   Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Final 12-Month, Open-Label Results [J].
Fernandez, Hubert H. ;
Standaert, David G. ;
Hauser, Robert A. ;
Lang, Anthony E. ;
Fung, Victor S. C. ;
Klostermann, Fabian ;
Lew, Mark F. ;
Odin, Per ;
Steiger, Malcolm ;
Yakupov, Eduard Z. ;
Chouinard, Sylvain ;
Suchowersky, Oksana ;
Dubow, Jordan ;
Hall, Coleen M. ;
Chatamra, Krai ;
Robieson, Weining Z. ;
Benesh, Janet A. ;
Espay, Alberto J. .
MOVEMENT DISORDERS, 2015, 30 (04) :500-509
[5]   Gastric emptying time and gastric motility in patients with Parkinson's disease [J].
Hardoff, R ;
Sula, M ;
Tamir, A ;
Soil, A ;
Front, A ;
Badarna, S ;
Honigman, S ;
Giladi, N .
MOVEMENT DISORDERS, 2001, 16 (06) :1041-1047
[6]   A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia [J].
Hauser, RA ;
Friedlander, J ;
Zesiewicz, TA ;
Adler, CH ;
Seeberger, LC ;
O'Brien, CF ;
Molho, ES ;
Factor, SA .
CLINICAL NEUROPHARMACOLOGY, 2000, 23 (02) :75-81
[7]   Levodopa: Past, Present, and Future [J].
Hauser, Robert A. .
EUROPEAN NEUROLOGY, 2009, 62 (01) :1-8
[8]   ERRATIC GASTRIC-EMPTYING OF LEVODOPA MAY CAUSE RANDOM FLUCTUATIONS OF PARKINSONIAN MOBILITY [J].
KURLAN, R ;
ROTHFIELD, KP ;
WOODWARD, WR ;
NUTT, JG ;
MILLER, C ;
LICHTER, D ;
SHOULSON, I .
NEUROLOGY, 1988, 38 (03) :419-421
[9]   THE EFFECT OF L-LEUCINE ON THE ABSORPTION OF LEVODOPA, STUDIED BY REGIONAL JEJUNAL PERFUSION IN MAN [J].
LENNERNAS, H ;
NILSSON, D ;
AQUILONIUS, SM ;
AHRENSTEDT, O ;
KNUTSON, L ;
PAALZOW, LK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (03) :243-250
[10]  
NUTT JG, 1984, CLIN NEUROPHARMACOL, V7, P35